» Articles » PMID: 35493456

The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression

Overview
Journal Front Immunol
Date 2022 May 2
PMID 35493456
Authors
Affiliations
Soon will be listed here.
Abstract

A fundamental concern of the majority of cancer scientists is related to the identification of mechanisms involved in the evolution of neoplastic cells at the cellular and molecular level and how these processes are able to control cancer cells appearance and death. In addition to the genome contribution, such mechanisms involve reciprocal interactions between tumor cells and stromal cells within the tumor microenvironment (TME). Indeed, tumor cells survival and growth rely on dynamic properties controlling pro and anti-tumorigenic processes. The anti-tumorigenic function of the TME is mainly regulated by immune cells such as dendritic cells, natural killer cells, cytotoxic T cells and macrophages and normal fibroblasts. The pro-tumorigenic function is also mediated by other immune cells such as myeloid-derived suppressor cells, M2-tumor-associated macrophages (TAMs) and regulatory T (Treg) cells, as well as carcinoma-associated fibroblasts (CAFs), adipocytes (CAA) and endothelial cells. Several of these cells can show both, pro- and antitumorigenic activity. Here we highlight the importance of the reciprocal interactions between tumor cells and stromal cells in the self-centered behavior of cancer cells and how these complex cellular interactions control tumor progression and repression.

Citing Articles

Genomic and micro-environmental insights into drug resistance in colorectal cancer liver metastases.

Kuang J, Li J, Zhou S, Li Y, Lin J, Huang W Discov Oncol. 2025; 16(1):241.

PMID: 40009285 PMC: 11865409. DOI: 10.1007/s12672-025-01976-8.


Innovative landscapes in intraperitoneal therapy of ovarian cancer.

Kumar K, Madhusoodanan M, Pangath M, Menon D Drug Deliv Transl Res. 2025; .

PMID: 39888579 DOI: 10.1007/s13346-024-01765-w.


High Expression of TBC1 Domain Family Member 22A is Related to Poor Prognosis in Ovarian Serous Cystadenocarcinoma.

Lv X, Gong R, Guo L, Wang C Int J Med Sci. 2024; 21(13):2603-2612.

PMID: 39439452 PMC: 11492882. DOI: 10.7150/ijms.99744.


Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics.

Muteeb G, Khafaga D, El-Morsy M, Farhan M, Aatif M, Hosney M Heliyon. 2024; 10(18):e37217.

PMID: 39309874 PMC: 11415663. DOI: 10.1016/j.heliyon.2024.e37217.


Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer.

Sayan M, Tuac Y, Akgul M, Kucukcolak S, Tjio E, Akbulut D Int J Mol Sci. 2024; 25(16).

PMID: 39201599 PMC: 11354361. DOI: 10.3390/ijms25168913.


References
1.
Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q . Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One. 2011; 6(4):e19495. PMC: 3084880. DOI: 10.1371/journal.pone.0019495. View

2.
Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

3.
Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J . Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014; 5:75. PMC: 3942647. DOI: 10.3389/fphys.2014.00075. View

4.
Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

5.
Tyan S, Kuo W, Huang C, Pan C, Shew J, Chang K . Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 2011; 6(1):e15313. PMC: 3020942. DOI: 10.1371/journal.pone.0015313. View